London - Jan 29
‍New York - Jun 11

Leveraged Finance Fights Melanoma

The premier convening of the leveraged finance community, coming together to fight melanoma, the deadliest form of skin cancer.

New York

June 11, 2025
Museum of Modern Art
Become a SponsorLearn more

London

Jan. 29, 2025
The National Gallery
Learn more
Join over 1,200 professionals from the investment, private equity, and leveraged finance communities to raise critical funds to advance life-saving melanoma research.
New YorkLondon
Since 2011, LFFM co-founders Jeffrey Rowbottom and Brendan Dillon — both personally touched by melanoma — have galvanized this annual event to raise over $27 million, directly fueling groundbreaking research and skin cancer prevention efforts.
New YorkLondon
New York
London

For more information on sponsorships and event information, please contact Janine Rauscher at jrauscher@curemelanoma.org.

2025 Global Sponsors

Full LFFM NY 2025 sponsor listing to be announced.

LFFM New York Co-Chairs

Clare Bailhé (MidCap Financial)
Brendan Dillon (Veritas Capital)
Kerry Dolan (Brinley Partners)
Chris Edson (Apollo)
Lee Grinberg (Elliot Management)
Jason Kanner (Kirkland & Ellis)
Eliza McDougall (White & Case)
Erwin Mock (Thoma Bravo)
George Mueller (KKR)
Geoff Oltmans (Silver Lake)
Jeff Rowbottom (General Atlantic)
Mark Rubenstein (HPS)
Ian Schuman (Latham & Watkins)
Brian Steinhardt (Simpson Thacher & Bartlett)
Cade Thompson (KKR)
Jason Van Dussen (Golub)
Trevor Watt (Hellman & Friedman)
Eric Wedel (Paul, Weiss, Rifkind, Wharton & Garrison)

“Our industry recognizes the profound impact of our support in driving cutting-edge research, leading to groundbreaking advancements in immunotherapies that are revolutionizing cancer treatment.”

Jeff Rowbottom

LFFM co-founder
“LFFM events offer hope to everyone affected by cancer – patients, survivors, and their loved ones – by ensuring researchers have the necessary resources to continue accelerating lifesaving discoveries.”

Jeff Rowbottom

LFFM co-founder

LFFM New York Steering Committee

James Bonetti (GTCR)
Livia Carega (Tiger Global)
Jennifer Corwin (Citadel)
Jennifer DeFazio (Morgan Stanley)
Damian Dovi (Benefit Street Partners)
Matthew Fuller (LevFin Insights)
Sidd Ghosh (Fitch Ratings)
Lauren Hanrahan (Milbank)
Kevin Lawi (UBS)
Matt Manin
Greg Middleman (Freedom Mortgage)

Matthew Middleton (Veritas Capital)
Melissa Saint Amour (Natixis)
Kevin Pluff (HPS)
Dhruv Sarna (Stone Point Capital)
Matthew Savino (The Carlyle Group)
Anna Schroeder (Bank of America)
John Stroll
Amanda Taitz (KKR)
Stephanie Teicher (Latham & Watkins)
Ramy Toma (General Atlantic)

For more information on sponsorships and event information, please contact Janine Rauscher at jrauscher@curemelanoma.org.

2025 Global Sponsors

2025 Platinum Sponsors

2025 Gold Sponsors

2025 Preferred Sponsors
2025 Advocate Sponsors

LFFM London Co-Chairs

Sean Costello (Fitch Ratings)
Roxana Mirica (Apax Partners)
Valeria Mollova (Apollo)
Tara Moore (Golub Capital)
Leo Wouters (General Atlantic)

LFFM London Host Committee

Peter Atkinson (HPS)
Ian Barratt (Kirkland & Ellis)
Juan Campos (Hg Capital)
Mike Carruthers (Blackstone Credit)
Conor Daly (CIFC)
Phil Edmans (Inflexion)
John Empson (CVC Credit)
Colin Harley (White & Case)
Todd Hooper (HPS)
Akshat Khaitan (KKR Capital Markets)

Simona Maellare (UBS)
Dipish Rai (Termgrid)
Neel Sachdev (Paul Weiss)
Chris Scott (Carlyle)
Stephen Smith (Sona)
Rich Trobman (Latham & Watkins)
Peter Urquhart (London Stock Exchange Group)
David Witkin (PSP Investments)

“The MRA has not only advanced understanding of this aggressive cancer [melanoma], but the research has also benefited broader oncology fields improving outcomes in lung, breast, and pancreatic cancers among others.”

Valeria Mollova, London Co-Chair

Apollo

Press

Inaugural Leveraged Finance Fights Melanoma London Raises £1.4 Million Benefiting the Melanoma Research Alliance

More about LFFM

MRA’s research advancements, supported by LFFM, have transformed the melanoma landscape, bringing 15 of the 17 new treatments to market since LFFM’s launch. The impact extends beyond melanoma, as therapies pioneered here are now being explored across more than 30 types of cancer, setting new standards in oncology.

Leveraged finance visionary pioneers such as Michael Milken, Leon Black, Carl Icahn, Henry Kravis, and Howard Marks have headlined this flagship event.

Leveraged Finance Fights Melanoma event in New York City
Leveraged Finance Fights Melanoma event in New York City
Leveraged Finance Fights Melanoma event in New York City
Leveraged Finance Fights Melanoma event in New York City
Leveraged Finance Fights Melanoma event in New York City - food
Leveraged Finance Fights Melanoma event in New York City
Leveraged Finance Fights Melanoma event in New York City
FAQS

Frequently Asked Questions

How do I purchase individual tickets?

At this time, individual tickets are not available for either the New York or the London event. To attend, you must become a sponsor, or attend as a guest of a current sponsor.

How do I become a sponsor?

Sponsorship opportunities can be found here (link to current sponsor decks). For more information, please contact Janine Rauscher, jrauscher@curemelanoma.org.

Are there opportunities for the press to attend?

Yes. Please contact Dana Deighton, Director of Communications and Engagement, ddeighton@curemelanoma.org.

What is the dress code for the event?

The dress code is business.

What is the format of the event? Is this a sit-down dinner?

The event is a networking cocktail reception. As such, there are no tables, but plenty of food & drink!